We appreciate the important contribution of Tibau et al. (1) in evaluation of the magnitude of clinical benefit of US Food and Drug Administration (FDA)–approved anticancer agents. The authors report the proportion of FDA-approved indications meeting the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.0 threshold of scores for substantial clinical benefit (A and B for curative treatments or 4 or 5 for noncurative treatments, which the authors have used as a threshold for “meaningful clinical benefit”).

中文翻译：

---

RE：美国食品药品监督管理局（FDA）批准的抗癌药物的临床益处的数量级

我们感谢Tibau等人的重要贡献。（1）在评估美国食品药品监督管理局（FDA）批准的抗癌药的临床益处时。作者报告了满足欧洲医学肿瘤学会临床效益量表（ESMO-MCBS）v1.0实质临床效益评分阈值阈值的FDA批准适应症的比例（治愈性疗法为A和B，非治愈性为4或5作者将其用作“有意义的临床获益”的门槛）。